Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06079671 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | PHASE3 | RECRUITING | 800 | — | — | Sep 22, 2023 | Sep 30, 2030 | May 27, 2026 | 204 | United States, Brazil +17 |
| NCT06943833 | A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) | PHASE2 | ACTIVE NOT_RECRUITING | 37 | — | — | Mar 31, 2025 | Mar 13, 2029 | May 19, 2026 | 12 | Russia |
PFS is defined as the time from date of randomization until RECIST 1.1- defined radiological progression or histopathologically confirmed progression as assessed by the Investigator or death due to any cause, whichever occurs earlier.
PFS24 is defined as the Kaplan-Meier estimate of PFS at 24 months per RECIST 1.1 or histopathologically confirmed progression as assessed by the Investigator or death due to any cause, whichever occurs earlier.
| Arm | Type | Description |
|---|---|---|
| Volrustomig | EXPERIMENTAL | Volrustomig |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Arm 1 | EXPERIMENTAL | Volrustomig |
| Name | Type | Description |
|---|---|---|
| Volrustomig | BIOLOGICAL | IV Infusion |
| Placebo | OTHER | IV Infusion |
Inclusion Criteria: For inclusion in the study, patients should fulfill the following criteria: 1. Female. 2. Aged at least 15 years at the time of screening. Note: Participants \< 18 years of age: physical changes should be aligned with Tanner Stage III. 3. Body weight \> 35 kg. 4. Histologically...